CORONA Remedies Limited Q4 FY26 results press release summary

Results press release of 11 May 2026, summarised by AI from the filing.

CORONA Remedies FY26 revenue ₹1,403.2 cr (+17.3%) and PAT ₹199.4 cr (+33.4%), driven by brand building and portfolio expansion.

Key takeaways

1. Guidance No forward guidance was provided in the release.
2. Acquisition Acquired WOKADINE, entering the ₹648 cr Povidone Iodine market, funded through internal accruals.
3. Growth driver Brand-building initiatives and portfolio expansion drove revenue growth.
4. Risk Forward-looking statements involve risks and uncertainties that are difficult to predict.

Original filing on BSE

CORONA Remedies Limited Q1 FY27 results

As filed: Revenue ₹422 cr, EBITDA ₹93.1 cr, PAT ₹60.1 cr, EBITDA margin 22.1%.

Not scored. No result for the same quarter last year.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹353 cr, EBITDA ₹62.0 cr, PAT ₹45.1 cr, EBITDA margin 17.6%. Not scored. No result for the same quarter last year. Share price after the results: −1.2% in 30 days (Nifty 500: −2.5%).
• Q3 FY26: Revenue ₹342 cr, EBITDA ₹83.2 cr, PAT ₹41.3 cr, EBITDA margin 24.3%. Not scored. No result for the same quarter last year. Share price after the results: +2.5% in 28 days (Nifty 500: −4.2%).

Past price moves after results do not indicate future moves. Not a recommendation.

CORONA Remedies Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (3 Aug 2026), Results deck (31 Jul 2026), Results press release (31 Jul 2026)
• Q4 FY26: Earnings call (12 May 2026), Results deck (11 May 2026), Results press release (11 May 2026)
• Q3 FY26: Earnings call (3 Feb 2026), Results deck (2 Feb 2026), Results press release (2 Feb 2026)
• Q2 FY26: Earnings call (5 Jan 2026), Results deck (3 Jan 2026), Results press release (2 Jan 2026)